Related: The Power of Genome Editing: What Investors Should Know

Some investors remain bullish on biotech and see more upside ahead for the sector and the related ETFs.

“Since hitting its lows on Dec. 26, the group had soared more than 20 percent as of Friday, and was posting its best start to a year since 2012. And according to Washington Crossing Advisors portfolio manager Chad Morganlander, the good times are set to roll on,” according to CNBC.

For more information on the healthcare sector, visit our healthcare category.